SNCAG — Synuclein Gamma

Migration, Crosslink

📖

SNCAG — Synuclein Gamma

active

wiki page Created: 2026-04-02T07:19:17 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-sncag

📖 Wiki Page

gene1895 wordssynced 2026-04-02

SNCAG — Synuclein Gamma

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SNCAG — Synuclein Gamma</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SNCAG</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Synuclein Gamma</td>
</tr>
<tr>
<td class="label">Synonyms</td>
<td>SNCG, PIG3, G1-NA-7</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>10q23.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/6623" target="_blank">6623</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108666" target="_blank">ENSG00000108666</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O76099" target="_blank">O76099</a></td>
</tr>
<tr>
<td class="label">Protein</td>
<td>[Synuclein Gamma Protein](/proteins/sncag-protein)</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>Synuclein family</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

SNCAG — Synuclein Gamma

Overview

...

SNCAG — Synuclein Gamma

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SNCAG — Synuclein Gamma</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SNCAG</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Synuclein Gamma</td>
</tr>
<tr>
<td class="label">Synonyms</td>
<td>SNCG, PIG3, G1-NA-7</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>10q23.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/6623" target="_blank">6623</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108666" target="_blank">ENSG00000108666</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O76099" target="_blank">O76099</a></td>
</tr>
<tr>
<td class="label">Protein</td>
<td>[Synuclein Gamma Protein](/proteins/sncag-protein)</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>Synuclein family</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

SNCAG — Synuclein Gamma

Overview

SNCAG (Synuclein Gamma) is a gene located on chromosome 10q23.2 that encodes the synuclein gamma protein (γ-synuclein). Along with [alpha-synuclein](/proteins/alpha-synuclein) (SNCA) and [beta-synuclein](/proteins/beta-synuclein) (SNCB), synuclein gamma is a member of the synuclein family of intrinsically disordered proteins. While alpha-synuclein is well-known for its central role in Parkinson's disease pathogenesis, synuclein gamma has distinct expression patterns and biological functions, with roles in both neurodegeneration and cancer biology[@galvin1999][@jensen2003].

The gene is catalogued as NCBI Gene ID [6623](https://www.ncbi.nlm.nih.gov/gene/6623) and UniProt [O76099](https://www.uniprot.org/uniprot/O76099).

Gene and Protein Structure

Gene Organization

The SNCAG gene spans approximately 4.5 kb on chromosome 10q23.2 and consists of 5 exons. The gene encodes a 127-amino acid protein with a molecular weight of approximately 14 kDa. Like other synucleins, the protein lacks a signal peptide and is primarily cytosolic.

Protein Domain Architecture

The synuclein gamma protein can be divided into three functional regions:

N-terminal region (aa 1-60): Contains 7 imperfect repeats of the 11-residue motif shared with alpha and beta-synuclein. This region is involved in membrane binding and may contribute to aggregation propensity. The repeat motifs contain the sequence "KTKEGV" which is conserved across all synuclein family members.

Central region (aa 61-95): The non-amyloid component (NAC) region, which contains the core amyloid-forming sequence. This region is highly hydrophobic and drives protein aggregation. The NAC region of gamma-synuclein shares significant homology with alpha-synuclein.

C-terminal region (aa 96-127): Acidic tail rich in aspartate and glutamate residues. This region likely regulates protein-protein interactions and may have protective effects against aggregation. The negative charge at physiological pH prevents premature aggregation.

Normal Biological Function

Expression Pattern

Synuclein gamma shows a distinct expression pattern compared to alpha-synuclein:

Brain: Expressed in sensory neurons, motor neurons, and specific brain regions including the thalamus, hippocampus, and cerebellum
Peripheral nervous system: High expression in dorsal root ganglia
Other tissues: Expressed in various peripheral tissues including heart, skeletal muscle, and pancreas
Cellular localization: Primarily cytosolic, with some membrane association

Physiological Roles

Chaperone function: Like other synucleins, gamma-synuclein exhibits molecular chaperone activity, helping to prevent protein aggregation under cellular stress. It can inhibit thermally-induced protein aggregation in vitro.

Modulation of dopamine transmission: In dopaminergic neurons, synuclein gamma may modulate dopamine synthesis and release, though its role is distinct from alpha-synuclein. Studies suggest it may have neuroprotective effects in some contexts.

Cancer biology: Elevated synuclein gamma expression is observed in multiple cancers (breast, ovarian, prostate) where it promotes cell proliferation and survival through p53 pathway modulation and other mechanisms[@sharma2016].

Neuronal development: May play roles in neuronal differentiation and process outgrowth during development.

Role in Neurodegeneration

Parkinson's Disease

While not as extensively studied as alpha-synuclein, synuclein gamma has been implicated in Parkinson's disease[@todorovic2019]:

Aggregation propensity: Like alpha-synuclein, gamma-synuclein can form amyloid aggregates under certain conditions, though it is not the primary component of Lewy bodies. It can co-aggregate with alpha-synuclein in vitro.

Interaction with alpha-synuclein: Studies suggest synuclein gamma may interact with alpha-synuclein and influence its aggregation behavior. It may seed alpha-synuclein aggregation under certain conditions.

Protective vs. pathogenic roles: Evidence is mixed - some studies suggest neuroprotective functions while others indicate potential contribution to pathology. Its exact role remains to be fully elucidated.

Genetic associations: Some studies have linked SNCAG polymorphisms with PD risk, though results have been inconsistent across populations.

Other Neurodegenerative Diseases

Alzheimer's disease: Limited evidence for direct involvement
ALS: Some studies show altered expression in motor neuron disease
Peripheral neuropathies: May play roles in diabetic neuropathy

Interaction Network

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| Alpha-synuclein (SNCA) | Protein-protein interaction | May influence aggregation |
| Beta-synuclein (SNCB) | Protein-protein interaction | Family member |
| p53 (TP53) | Transcriptional regulation | PIG3 name origin |
| Hsp70 | Chaperone interaction | Protein folding |
| Cyclin-dependent kinases | Interaction | Cell cycle modulation |

Cancer Associations

Synuclein gamma has been more extensively studied in cancer context[@ninkina2021]:

| Cancer Type | Expression | Role |
|-------------|------------|------|
| Breast cancer | Elevated | Promotes proliferation, metastasis |
| Ovarian cancer | Elevated | Associated with poor prognosis |
| Prostate cancer | Elevated | Enhances cell survival |
| Colorectal cancer | Variable | Context-dependent |

The protein has also been referred to as PIG3 (p53-induced gene 3), linking it to p53-mediated apoptosis pathways.

Oncogenic Mechanisms

Beyond neurodegeneration, synuclein gamma has significant roles in cancer:

Cell Proliferation: Promotes cell cycle progression through interaction with cyclin-dependent kinases and modulation of p53 pathways.

Cell Survival: Inhibits apoptosis through PI3K/Akt signaling activation and mitochondrial protection.

Metastasis: Enhances invasive behavior through EMT modulation and matrix metalloproteinase expression.

Genetic Variants and Disease Associations

Known Pathogenic Variants

While most studies focus on alpha-synuclein, several SNCAG variants have been described:

Missense variants with altered aggregation properties
Variants affecting expression levels
Rare variants associated with increased PD risk

Animal Models

Transgenic mice: Mouse models expressing human synuclein gamma show age-dependent neuronal dysfunction, motor deficits in some lines, and alpha-synuclein co-localization in some studies.

Zebrafish models: Knockdown studies reveal developmental abnormalities, dopaminergic neuron loss, and behavioral deficits.

Therapeutic Implications

Targeting Strategies

Small molecule inhibitors: Development of compounds that prevent synuclein gamma aggregation, potentially targeting both alpha and gamma-synuclein

RNAi/ASO approaches: Reducing expression through gene silencing

Immunotherapy: Antibody-based approaches (less advanced than alpha-synuclein)

Biomarker Potential

Cancer: Serum synuclein gamma as a potential biomarker for tumor burden and treatment response
Neurodegeneration: Less established than alpha-synuclein, but CSF measurements under investigation

Synuclein Family Comparison

| Feature | Alpha-Synuclein (SNCA) | Beta-Synuclein (SNCB) | Gamma-Synuclein (SNCAG) |
|---------|----------------------|---------------------|----------------------|
| Amino acids | 140 | 134 | 127 |
| Chromosome | 4q21 | 5q12 | 10q23 |
| Main pathology | Lewy bodies | Less aggregation | Secondary role |
| Cancer link | Limited | Limited | Strong |
| Therapeutic focus | High | Moderate | Emerging |

Summary

SNCAG encodes synuclein gamma, a member of the synuclein family with distinct roles in both neurodegeneration and cancer. While alpha-synuclein remains the primary focus in Parkinson's disease research, gamma-synuclein offers unique insights into:

Aggregation mechanisms common to the synuclein family
Connections between neurodegeneration and cancer biology
Potential as a dual-purpose biomarker

Understanding synuclein gamma's functions and mechanisms provides a more complete picture of the synuclein family in health and disease.

Molecular Mechanisms in Neurodegeneration

The pathogenesis of neurodegeneration in synucleinopathies involves multiple cellular pathways that gamma-synuclein participates in:

Aggregation Pathway: The process of synuclein gamma aggregation follows a nucleation-dependent mechanism:

Monosynuclein gamma exists in a cytosolic disordered state

Under cellular stress, oligomeric intermediates form (toxic species)

Fibril nucleation occurs, potentially seeded by pre-existing alpha-synuclein fibrils

Stable amyloid fibrils accumulate in neurons

These aggregates may incorporate into Lewy bodies over time

Cellular Toxicity Mechanisms: Multiple pathways contribute to neurodegeneration:

Membrane permeabilization: Oligomeric synuclein gamma can disrupt cellular membranes
ER stress: Protein folding impairment activates unfolded protein response
Mitochondrial dysfunction: Direct interaction with mitochondrial proteins
Oxidative stress: Increased reactive oxygen species generation
Synaptic impairment: Disruption of synaptic vesicle function

Cross-talk with Alpha-Synuclein: The interaction between gamma and alpha-synuclein is complex:

Direct protein-protein binding influences aggregation kinetics
Gamma-synuclein can seed alpha-synuclein fibril formation
Both proteins may compete for cellular clearance mechanisms
Shared vulnerabilities in dopaminergic neurons

Research Directions

Current research focuses on several key areas:

Biomarker Development: Efforts to establish synuclein gamma as a clinical biomarker include:

Developing sensitive immunoassays for CSF and plasma detection
Correlating levels with disease progression
Identifying disease-specific signatures

Therapeutic Development: Targeting synuclein gamma therapeutically involves:

Small molecules that inhibit aggregation
Gene silencing approaches (RNAi, ASO)
Immunotherapy targeting gamma-synuclein specifically

Model Systems: Understanding gamma-synuclein biology requires:

Development of better animal models
Induced pluripotent stem cell (iPSC) models
3D neuronal culture systems

Clinical Considerations

While synuclein gamma is not currently a primary therapeutic target in the clinic, several considerations apply:

Diagnostic relevance: Synuclein gamma measurements may complement alpha-synuclein assessments in:

Differential diagnosis of synucleinopathies
Disease subtype classification
Monitoring disease progression

Research eligibility: Patients with synucleinopathies may be eligible for clinical trials targeting:

Alpha-synuclein aggregation
General neuroprotective mechanisms
Disease modification strategies

Future directions: As understanding of gamma-synuclein improves, its role in clinical practice may expand to include:

Targeted therapies specifically addressing gamma-synuclein
Personalized medicine approaches based on synuclein profiles
Combination therapies addressing multiple synuclein forms

Evolutionary Perspective

The synuclein family has evolved with distinct functions across species:

Conservation: Gamma-synuclein shows significant conservation across vertebrates:

Zebrafish (danio rerio) ortholog shares 75% amino acid identity
Mouse and rat orthologs share 95% identity with human protein
Evolutionary emergence suggests distinct functional niches

Gene family evolution: The three synuclein genes likely arose from gene duplication events:

Alpha and beta synuclein are most closely related
Gamma-synuclein diverged earlier in evolution
Each paralog developed specialized functions

Functional divergence: Different synucleins acquired distinct roles:

Alpha-synuclein: primary neuronal function, aggregation in disease
Beta-synuclein: neuroprotective, anti-aggregation activity
Gamma-synuclein: neuronal and non-neuronal functions, cancer link

Comparison with Alpha-Synuclein Biology

Understanding gamma-synuclein requires comparing it to the better-characterized alpha-synuclein:

Structural similarities: Both proteins share the same overall domain organization with:

N-terminal membrane-binding repeats
Central hydrophobic NAC region
C-terminal acidic tail

Functional differences: Key distinctions include:

Alpha-synuclein is the primary component of Lewy bodies
Gamma-synuclein may have more prominent roles outside the brain
Different expression patterns in health and disease

Therapeutic implications: These differences have therapeutic relevance:

Alpha-synuclein remains the primary therapeutic target
Gamma-synuclein may provide secondary therapeutic benefit
Understanding both informs comprehensive treatment strategies

Historical Discovery

The identification and characterization of synuclein gamma represents an important chapter in neuroscience research:

Initial discovery: Gamma-synuclein was first identified in the late 1990s as a protein enriched in the brain and subsequently found to be elevated in various cancers.

PIG3 connection: The discovery of its identity as p53-induced gene 3 (PIG3) revealed its dual role in both cell death pathways and oncogenesis.

Ongoing research: Since its initial characterization, research has progressively revealed the complex biology of gamma-synuclein, from its physiological functions to its contributions to disease processes.

The gamma-synuclein story illustrates the broader principle that proteins often serve multiple functions across different biological contexts, and understanding these diverse roles is essential for comprehensive disease models.

External Links

NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/6623](https://www.ncbi.nlm.nih.gov/gene/6623)
Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108666](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108666)
UniProt: [https://www.uniprot.org/uniprot/O76099](https://www.uniprot.org/uniprot/O76099)

slug	genes-sncag
kg_node_id	SNCAG
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-91b7722d203a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-sncag'}
_schema_version	1

📗 Cite This Artifact

SNCAG — Synuclein Gamma

SNCAG — Synuclein Gamma

SNCAG — Synuclein Gamma

Overview

SNCAG — Synuclein Gamma

SNCAG — Synuclein Gamma

Overview

Gene and Protein Structure

Gene Organization

Protein Domain Architecture

Normal Biological Function

Expression Pattern

Physiological Roles

Role in Neurodegeneration

Parkinson's Disease

Other Neurodegenerative Diseases

Interaction Network

Cancer Associations

Oncogenic Mechanisms

Genetic Variants and Disease Associations

Known Pathogenic Variants

Animal Models

Therapeutic Implications

Targeting Strategies

Biomarker Potential

Synuclein Family Comparison

Summary

Molecular Mechanisms in Neurodegeneration

Research Directions

Clinical Considerations

Evolutionary Perspective

Comparison with Alpha-Synuclein Biology

Historical Discovery

External Links

See Also

💬 Discussion